Last updated: 4 July 2020 at 1:06pm EST

Abid Ansari Net Worth




The estimated Net Worth of Abid Ansari is at least $1.52 Milion dollars as of 15 June 2020. Abid Ansari owns over 8,783 units of Precision BioSciences stock worth over $1,516,211 and over the last 5 years Abid sold DTIL stock worth over $0.

Abid Ansari DTIL stock SEC Form 4 insiders trading

Abid has made over 4 trades of the Precision BioSciences stock since 2019, according to the Form 4 filled with the SEC. Most recently Abid exercised 8,783 units of DTIL stock worth $10,540 on 15 June 2020.

The largest trade Abid's ever made was exercising 103,645 units of Precision BioSciences stock on 10 June 2019 worth over $124,374. On average, Abid trades about 23,715 units every 62 days since 2019. As of 15 June 2020 Abid still owns at least 144,401 units of Precision BioSciences stock.

You can see the complete history of Abid Ansari stock trades at the bottom of the page.



What's Abid Ansari's mailing address?

Abid's mailing address filed with the SEC is C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701.

Insiders trading at Precision BioSciences

Over the last 6 years, insiders at Precision BioSciences have traded over $352,500 worth of Precision BioSciences stock and bought 224,670 units worth $1,909,002 . The most active insiders traders include Raymond F Schinazi, Llc Fmr oraz Michael Amoroso. On average, Precision BioSciences executives and independent directors trade stock every 22 days with the average trade being worth of $357,735. The most recent stock trade was executed by Dario Scimeca on 7 June 2024, trading 301 units of DTIL stock currently worth $3,161.



What does Precision BioSciences do?

Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.



What does Precision BioSciences's logo look like?

Precision BioSciences, Inc. logo

Complete history of Abid Ansari stock trades at Precision BioSciences

Data
#
Firma
Osoba
Trans.
Transakcja
Ilość akcji Cena za akcję Łączna cena Ilość akcji po Źródło
15 Jun 2020 Abid Ansari
Dyrektor finansowy
Opcja Ćwiczenie 8,783 $1.20 $10,540
15 Jun 2020
144,401
15 May 2020 Abid Ansari
Dyrektor finansowy
Opcja Ćwiczenie 9,661 $1.20 $11,593
15 May 2020
135,618
6 Jan 2020 Abid Ansari
Dyrektor finansowy
Opcja Ćwiczenie 20,200 $1.20 $24,240
6 Jan 2020
123,845
10 Jun 2019 Abid Ansari
Dyrektor finansowy
Opcja Ćwiczenie 103,645 $1.20 $124,374
10 Jun 2019
103,645


Precision BioSciences executives and stock owners

Precision BioSciences executives and other stock owners filed with the SEC include: